Literature DB >> 4996227

Laboratory and pharmacologic studies of BL-P-1322 (cephapirin sodium) in children.

R C Gordon, F F Barrett, D J Clark, M D Yow.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1971        PMID: 4996227

Source DB:  PubMed          Journal:  Curr Ther Res Clin Exp        ISSN: 0011-393X


× No keyword cloud information.
  8 in total

Review 1.  Newer beta-lactam antibiotics.

Authors:  J M Hamilton-Miller; W Brumfitt
Journal:  Infection       Date:  1974       Impact factor: 3.553

2.  Treatment of pneumonia and other serious bacterial infections with cephapirin.

Authors:  H G Robson; M I Bowmer
Journal:  Antimicrob Agents Chemother       Date:  1974-09       Impact factor: 5.191

3.  Activity of four cephalosporin antibiotics in vitro against bovine udder pathogens and pathogenic bacteria isolated from newborn calves.

Authors:  G Ziv
Journal:  Antimicrob Agents Chemother       Date:  1976-03       Impact factor: 5.191

4.  Neutropenia associated with cephapirin therapy.

Authors:  M E Levison; J L Bran; J H Jepson; D Kaye
Journal:  Antimicrob Agents Chemother       Date:  1972-02       Impact factor: 5.191

5.  Effect of hemodialysis and renal failure on serum and urine concentrations of cephapirin sodium.

Authors:  R V McCloskey; E E Terry; A W McCracken; M J Sweeney; M F Forland
Journal:  Antimicrob Agents Chemother       Date:  1972-02       Impact factor: 5.191

6.  Evaluation of a new cephalosporin antibiotic, cephapirin.

Authors:  P Wiesner; R MacGregor; D Bear; S Berman; K Holmes; M Turck
Journal:  Antimicrob Agents Chemother       Date:  1972-04       Impact factor: 5.191

7.  Clinical and in vitro evaluation of cephapirin, a new cephalosporin antibiotic.

Authors:  J L Bran; M E Levison; D Kaye
Journal:  Antimicrob Agents Chemother       Date:  1972-01       Impact factor: 5.191

8.  Double-blind controlled comparison of phlebitis produced by cephapirin and cephalothin.

Authors:  J Carrizosa; M E Levison; D Kaye
Journal:  Antimicrob Agents Chemother       Date:  1973-02       Impact factor: 5.191

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.